| Ytd | 23.16% | |
| 1y | 29.49% |
| Open | 147.23 | Prev Close | 147.10 | Low | 146.10 | High | 151.44 | Mkt Cap | 187.44B |
| Vol | 5.80M | Avg Vol | 5.99M | EPS | -2.72 | P/E | N/A | Forward P/E | 15.29 |
| Beta | 0.33 | Short Ratio | 3.45 | Inst. Own | 92.19% | Dividend | 3.28 | Div Yield | 2.23 |
| Ex Div Date | 09-15 | Earning | 10-29 | 50-d Avg | 144.31 | 200-d Avg | 137.18 | 1yr Est | 159.38 |
GILD News
BBH concentrates on 25 large-cap biotech leaders, while XPH diversifies across 62 pharmaceutical hol
Gilead Sciences (GILD) closed the most recent trading day at $151.17, moving +2.77% from the previou
RBC Capital analyst Brian Abrahams maintains Gilead Sciences (NASDAQ:GILD) with a Sector Perform
Cantor Fitzgerald analyst Carter Gould reiterates Gilead Sciences (NASDAQ:GILD) with a Overweight
Truist Securities analyst Gregory Renza maintains Gilead Sciences (NASDAQ:GILD) with a Buy and ra
JP Morgan analyst Chris Schott maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and rais
Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:GILD) with a Overweight
Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the di
What happened Gilead Sciences, Inc. (NASDAQ: GILD) said Chairman and CEO and director Daniel Patrick
Gilead Sciences (GILD) closed the most recent trading day at $144.74, moving 1.87% from the previous
Gilead shares are up 35% since Barron's highlighted them, but our catalysts have yet to fully play o
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exp
In the latest trading session, Gilead Sciences (GILD) closed at $149.45, marking a -1.21% move from
Clinton warns abrupt HIV funding shifts could disrupt treatment and prevention, saying “a deadline i
Gilead Sciences, Inc. (NASDAQ: GILD - Get Free Report) has been assigned a consensus rating of "Mode
Today we highlight a discovery with potentially important implications for future Alzheimer's resear
The latest rebalance of VettaFi's Thematic Rotation Quality Momentum Screened Index (TQRMS), tracked
Envestnet Asset Management Inc. reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ: GILD)
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
Bristol Myers' growth portfolio and pipeline advances offer multiple ways to offset legacy-product e
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 5 years by 4.6% on an annual
MEXICO CITY--(BUSINESS WIRE)-- #Gilead--AIDS Healthcare Foundation (AHF), the world's largest HIV ca
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhil
GILD's PAHO deal expands twice-yearly lenacapavir access across Latin America and the Caribbean, add
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it h
PPH offers higher income and lower volatility, while BBH delivers stronger growth but with deeper dr
Gilead Sciences NASDAQ: GILD executives outlined plans to expand the company's HIV prevention and tr
Gilead Sciences, Inc. (GILD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Tra
Gilead Sciences, Inc. (Nasdaq: GILD) today announced a new agreement with the [url="]Pan American He
– Agreement Establishes a Regional Pathway Through PAHO’s Regional Revolving Funds to Support Countr
U.S. drugmaker Gilead Sciences said on Tuesday it had reached an agreement with the Pan American Hea
- conference call
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 2.42% on an annu
HSBC analyst Morten Herholdt maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the pr
The FDA approved Gilead Sciences' Bixlenvo, a new once-daily single tablet regimen for virologic
https://www.who.int/news/item/28-08-2026-second-meeting-of-the-ihr-emergency-committee-on-the-epidem
Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA)
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 5 years by 4.4% on an annual
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the European Commission (EC) has granted ma
Joshua Brown chose Snowflake Inc., while Rob Sechan picked KLA Corp and Brian Belski recommended Gil
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 2.04% on an annu
MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on developing in
Kathy Hochul says Trump's Medicare subsidy decision will raise prescription drug costs for 1.3 m
RBC Capital analyst Brian Abrahams maintains Gilead Sciences (NASDAQ:GILD) with a Sector Perform
Cantor Fitzgerald analyst Carter Gould reiterates Gilead Sciences (NASDAQ:GILD) with a Overweight
Needham analyst Joseph Stringer reiterates Gilead Sciences (NASDAQ:GILD) with a Buy and maintains
Gilead Sciences (NASDAQ:GILD) lowers FY2026 GAAP EPS guidance from $(3.25)-$(2.85) to $(3.75)-$(3.40
Gilead Sciences (NASDAQ:GILD) raises FY2026 Adj EPS guidance from $(1.05)-$(0.65) to $(0.65)-$(0.30)